Biodistribution of Amikacin Solid Lipid Nanoparticles after Pulmonary Delivery

The main purpose of the present work was studying the biodistribution of amikacin solid lipid nanoparticles (SLNs) after pulmonary delivery to increase its concentration in the lungs for treatment of cystic fibrosis lung infections and also providing a new method for clinical application of amikacin...

Full description

Saved in:
Bibliographic Details
Published inBioMed research international Vol. 2013; no. 2013; pp. 1 - 8
Main Authors Azarmi, S., Atyabi, Fatemeh, Jafarian, A., Mirshojaei, S. F., Ghaffari, S., Varshosaz, Jaleh, Kobarfard, F.
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Publishing Corporation 01.01.2013
John Wiley & Sons, Inc
Subjects
Amikacin
Amikacin - administration & dosage
Amikacin - blood
Amikacin - pharmacokinetics
Amikacin - pharmacology
Animals
Cystic fibrosis
Drug Administration Routes
Drug therapy
Health aspects
Lipids - pharmacokinetics
Lung - diagnostic imaging
Lung - drug effects
Lung - metabolism
Male
Nanoparticles
Nanoparticles - chemistry
Nanoparticles - ultrastructure
Particle Size
Radionuclide Imaging
Rats
Rats, Wistar
Research Article
Technetium - administration & dosage
Technetium - blood
Technetium - pharmacokinetics
Technetium - pharmacology
Tissue Distribution - drug effects
Iran
Online AccessGet full text

Cover

More Information
Summary:The main purpose of the present work was studying the biodistribution of amikacin solid lipid nanoparticles (SLNs) after pulmonary delivery to increase its concentration in the lungs for treatment of cystic fibrosis lung infections and also providing a new method for clinical application of amikacin. To achieve this aim, 99mTc labelled amikacin was loaded in cholesterol SLNs and after in vitro optimization, the desired SLNs and free drug were administered through pulmonary and i.v. routes to male rats and qualitative and biodistribution studies were done. Results showed that pulmonary delivery of SLNs of amikacin by microsprayer caused higher drug concentration in lungs than kidneys while i.v. administration of free drug caused reverse conditions. It seems that pulmonary delivery of SLNs may improve patients' compliance due to reduction of drug side effects in kidneys and elongation of drug dosing intervals due to the sustained drug release from SLNs.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
Academic Editor: Ruxana T. Sadikot
ISSN:2314-6133
2314-6141
DOI:10.1155/2013/136859